Sees FY19 revenue from royalties of $72M-$74M, with the decrease primarily attributable to the ongoing impact from biosimilars in Europe and updated expectations for the US launched products; product sales related to API increased to reflect additional customer orders; operating expenses of $265M-$275M, or $225M-$235M excluding an expected increase in cost of goods sold; operating cash burn of $45M-$55M; debt repayment of approximately $90Mm the company expects to pay off the remainder of the royalty-backed debt by the end of the Q1 of FY20; and year-end cash, cash equivalents and marketable securities balance of $210M-$220M.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.